GETI.B

197.85

+1.15%↑

EKTA.B

52.7

+0.67%↑

ATT

114

-3.31%↓

AMBEA

138.1

-1.57%↓

ARJOB

24.38

-0.25%↓

GETI.B

197.85

+1.15%↑

EKTA.B

52.7

+0.67%↑

ATT

114

-3.31%↓

AMBEA

138.1

-1.57%↓

ARJOB

24.38

-0.25%↓

GETI.B

197.85

+1.15%↑

EKTA.B

52.7

+0.67%↑

ATT

114

-3.31%↓

AMBEA

138.1

-1.57%↓

ARJOB

24.38

-0.25%↓

GETI.B

197.85

+1.15%↑

EKTA.B

52.7

+0.67%↑

ATT

114

-3.31%↓

AMBEA

138.1

-1.57%↓

ARJOB

24.38

-0.25%↓

GETI.B

197.85

+1.15%↑

EKTA.B

52.7

+0.67%↑

ATT

114

-3.31%↓

AMBEA

138.1

-1.57%↓

ARJOB

24.38

-0.25%↓

Search

Orexo AB

Open

20.9 8.52

Overview

Share price change

24h

Current

Min

19.24

Max

20.95

Key metrics

By Trading Economics

Income

41M

-75M

Sales

1.7M

5M

EPS

-3.812

Profit margin

-1,500

Employees

65

EBITDA

206M

-66M

Dividends

By Acuity

Next Earnings

16 lip 2026

Market Stats

By TradingEconomics

Market Cap

-35M

665M

Previous open

12.38

Previous close

20.9

Orexo AB Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
help-icon Live chat